2 assets in Lung Giant Cell Carcinoma

Therapeutic assets addressing Lung Giant Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Lung Giant Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Lung Giant Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)